Chemours Adopts Executive Severance Policy With Cash Severance for Executives
Chemours adopted an Executive Severance Policy on October 28, 2025, covering executive officers and certain designated employees. Under the policy, a CEO terminated without cause or resigning for good reason would receive 2.0 times the sum of base salary, target annual incentive and annualized health care subsidy, while other participants would receive 1.0 times that sum. The policy sets severance terms for participants but does not change existing change-in-control agreements or outstanding equity awards, so its effect on shareholders depends on how many people are designated and when terminations occur.
Key points
- Policy adopted by the Board on October 28, 2025, effective the same day.
- CEO cash severance: 2.0 times base salary, target annual incentive and annualized health care subsidy.
- Other executive officers and employees: 1.0 times the same sum.
- Participants must sign a release of claims; existing change-in-control agreements and equity awards are not superseded.
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.